According to GlobalData, Nevro is one of 128 product lines sold in the US neuromodulation devices market; these product lines are sold by 17 different manufacturers. The price of the Nevro device can be viewed in GlobalData’s micro pricing report and can be retrieved according to purchase date, facility type, bed size, and geographical region. Buy the report here.
The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches.
In addition, the final selling pricing of medical devices is also impacted by the discounting policy of the manufacturer. Companies such as Nevro apply discounts for their devices based on their internal business strategy, inventory control, and monthly or quarterly sales targets. In addition, sale location can also affect the final selling price of a device, both in terms of geographical region and facility type. Prices for the same medical device often vary in hospitals and health systems versus outside of hospital facilities, for example if high volume healthcare institutions can negotiate discounts or rebates based on large purchase sizes.
Nevro Corp (Nevro) is a medical device company, which is engaged in developing novel products that advance the quality of life for people suffering from chronic pain in trunks and limbs. The company has developed Nevro Senza spinal cord stimulation (SCS) system, a non-pharmacological neuromodulation platform for the treatment of chronic pain. The Nevro Senza SCS system is commercially available in the US, Europe, and Australia. The company offers products under Senza, Senza II, Senza Omnia and the Nevro logo brands. Nevro is developing HF10 therapy for treatment related to painful diabetic neuropathy and non-surgical refractory back pain. Nevro is headquartered in Redwood City, California, the US.